<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01064713</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0624</org_study_id>
    <secondary_id>NCI-2011-00557</secondary_id>
    <nct_id>NCT01064713</nct_id>
  </id_info>
  <brief_title>Phase II Study of Tesetaxel in Metastatic Melanoma</brief_title>
  <official_title>A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genta Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if tesetaxel can help to control&#xD;
      metastatic melanoma. The safety of this drug will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drug:&#xD;
&#xD;
      Tesetaxel is designed to block cancer cells from dividing, which may cause them to die.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be assigned to 1 of 2&#xD;
      Groups based on when you enroll in this study. Each group has 2 &quot;stages.&quot;&#xD;
&#xD;
      Group A:&#xD;
&#xD;
      A total of 27 patients will be enrolled in Group A and will receive a 40mg dose of tesetaxel,&#xD;
      adjusted for individual body weight. For Group A, 13 patients will be enrolled in Stage 1. If&#xD;
      at least 1 patient has a response to the 40 mg dose of tesetaxel, 14 additional patients will&#xD;
      be enrolled in Stage 2 at the same dose level.&#xD;
&#xD;
      Group B:&#xD;
&#xD;
      A total of 27 patients will be enrolled in Group B and will receive a 50mg dose of tesetaxel,&#xD;
      adjusted for individual body weight. For Group B, 13 patients will be enrolled in Stage 1&#xD;
      while researchers are waiting to see if patients in Group A respond to the study drug. If at&#xD;
      least 1 patient has a response to the 50 mg dose of tesetaxel, 14 additional patients will be&#xD;
      enrolled in Stage 2 at the same dose level.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      No matter which Group you are assigned to, you will take tesetaxel capsules by mouth in the&#xD;
      morning with water (6 ounces) on Day 1 of each 21-day study cycle. You must not eat or drink&#xD;
      anything except water (fast) for at least 4 hours before taking tesetaxel. After fasting for&#xD;
      4 hours and taking tesetaxel, you may eat an average sized meal.&#xD;
&#xD;
      Before you take tesetaxel, you will receive drugs to prevent nausea and vomiting. The study&#xD;
      doctor will discuss this with you. If you have a rash or allergic reaction, you may be&#xD;
      receive an antihistamine and/or corticosteroid. If you develop a low number of white blood&#xD;
      cells or red blood cells, you may be given growth factor drugs or receive transfusions. These&#xD;
      drugs may be given by mouth or vein.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      On Day 1 of all Cycles:&#xD;
&#xD;
      -Your medical history, including any side effects you may have had and any drugs you may be&#xD;
      taking, will be recorded.&#xD;
&#xD;
      On Day 9 (+/- 1 day) and again on Day 20 (+/- 2 days) of all Cycles:&#xD;
&#xD;
        -  Any side effects you may have had and any drugs you may be taking will be recorded.&#xD;
&#xD;
        -  Blood (about 2 teaspoons) will be drawn for routine tests.&#xD;
&#xD;
      Within 5 days before the start of cycles 3, 5, 7 and every other cycle thereafter:&#xD;
&#xD;
        -  You will have a CT scan of the chest, stomach, and hip areas.&#xD;
&#xD;
        -  Photographs of any melanoma on your skin will be taken.&#xD;
&#xD;
        -  Any side effects you may have had and any drugs you may be taking will be recorded.&#xD;
&#xD;
      After the last dose of tesetaxel, blood (about 2 teaspoons) will be drawn for routine tests.&#xD;
&#xD;
      Within 3 weeks after the last dose of tesetaxel:&#xD;
&#xD;
        -  You will have a CT scan of the chest, stomach, and hip areas.&#xD;
&#xD;
        -  Photographs of any melanoma on your skin will be taken.&#xD;
&#xD;
        -  Any side effects you may have had and any drugs you may be taking, will be recorded.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may continue taking the study drug for as long as the doctor thinks it is in your best&#xD;
      interest. You will no longer be able to take the study drug if the disease gets worse or&#xD;
      intolerable side effects occur.&#xD;
&#xD;
      Follow-Up Visits:&#xD;
&#xD;
      If the melanoma does not get worse while you are on study, you will have visits every 2&#xD;
      months for up to 12 months after your first dose of study drug. At these visits:&#xD;
&#xD;
        -  You will have a CT scan of the chest, stomach, and hip areas.&#xD;
&#xD;
        -  Photographs of any melanoma on your skin will be taken.&#xD;
&#xD;
        -  Any side effects you may have had and any drugs you may be taking, will be recorded.&#xD;
&#xD;
        -  You will be asked about any treatment you may be receiving.&#xD;
&#xD;
      If the disease gets worse while you are on study, you will have follow up phone calls every 2&#xD;
      months for up to 12 months after your first dose of study drug. During these calls, you will&#xD;
      be asked how you are feeling and about any therapy you are receiving. These calls should take&#xD;
      about 5 minutes.&#xD;
&#xD;
      This is an investigational study. Tesetaxel is not FDA approved or commercially available. It&#xD;
      is currently being used for research purposes only.&#xD;
&#xD;
      Up to 54 patients will take part in this study. All will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (ie, the Percentage of Subjects With a Confirmed Complete or Partial Response)</measure>
    <time_frame>Day 84</time_frame>
    <description>Determination of response performed according to the revised Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 using computed tomography (CT). Complete response: Disappearance of all target lesions; if pathologic lymph node, reduction in shortest axis to &lt; 10 mm; Partial response: ≥ 30% decrease in sum of diameters of target lesions relative to baseline sum diameters; Stable disease: Neither a sufficient reduction to qualify as partial response nor a sufficient increase to qualify as progression; Progressive disease ≥ 20% increase in sum diameters relative to smallest sum diameters recorded (including baseline sum diameters) in conjunction with increase of least 5 mm in that smallest sum diameters, or appearance of one or more new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Response</measure>
    <time_frame>Day 84</time_frame>
    <description>Determination of response performed according to the revised Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 using computed tomography (CT). Complete response: Disappearance of all target lesions; if pathologic lymph node, reduction in shortest axis to &lt; 10 mm; Partial response: ≥ 30% decrease in sum of diameters of target lesions relative to baseline sum diameters; Stable disease: Neither a sufficient reduction to qualify as partial response nor a sufficient increase to qualify as progression; Progressive disease ≥ 20% increase in sum diameters relative to smallest sum diameters recorded (including baseline sum diameters) in conjunction with increase of least 5 mm in that smallest sum diameters, or appearance of one or more new lesions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Advanced Melanoma</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Tesetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy initiated at a flat dose of 40 mg for subjects in Cohort A and at a flat dose of 50 mg for subjects in Cohort B. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesetaxel</intervention_name>
    <description>Cohort A: 40 mg by mouth every 21 days.&#xD;
Cohort B. 50 mg by mouth every 21 days.</description>
    <arm_group_label>Tesetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years of age.&#xD;
&#xD;
          2. Histologically confirmed diagnosis of melanoma.&#xD;
&#xD;
          3. Progressive disease that is not surgically resectable, or metastatic Stage IV disease.&#xD;
&#xD;
          4. Measurable disease.&#xD;
&#xD;
          5. Serum LDH &lt;/= 1.1 times the upper limit of normal (x ULN).&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group performance status 0 or 1.&#xD;
&#xD;
          7. Treatment with 1 prior regimen (including cytotoxic chemotherapy, immunotherapy,&#xD;
             radiation therapy, or cytokine, biologic, or vaccine therapy) as first-line treatment&#xD;
             for metastatic disease. (Administration of interleukin-2 or interferon as adjuvant&#xD;
             therapy is allowed and is not to be considered in determining the 1 prior treatment&#xD;
             regimen administered as first-line treatment for metastatic disease.)&#xD;
&#xD;
          8. Adequate bone marrow, hepatic, and renal function, as evidenced by: a) Absolute&#xD;
             neutrophil count (ANC) &gt;/= 1500/mm^3; b) Platelet count &gt;/= 100,000/mm^3; c)&#xD;
             Hemoglobin &gt;/= 9 g/dL without need for hematopoietic growth factor or transfusion&#xD;
             support; d) Aspartate aminotransferase (AST) &lt;/= 2.5 x ULN or, in the presence of&#xD;
             liver metastasis, &lt;/= 5 x ULN; e) Alanine aminotransferase (ALT) &lt;/= 2.5 x ULN or, in&#xD;
             the presence of liver metastasis, &lt;/= 5 x ULN f. Total bilirubin &lt;/= 1.5 x ULN;&#xD;
&#xD;
          9. (Continued # 8) g) Alkaline phosphatase &lt;/= 2.5 x ULN or, in the presence of liver&#xD;
             metastasis, &lt;/= 5 x ULN or, in the presence of bone metastasis, &lt;/= 10 x ULN; h) Serum&#xD;
             creatinine &lt;/= 1.5 x ULN; i) Serum albumin &gt;/= 3.0 g/dL; j) Prothrombin time (PT) &lt;/=&#xD;
             1.5 x ULN (or international normalized ratio [international normalized ratio (INR)]&#xD;
             &lt;/=1.3); k) Partial thromboplastin time (PTT) &lt;/= 1.5 x ULN.&#xD;
&#xD;
         10. At least 3 weeks and recovery from effects of prior surgery or other therapy with an&#xD;
             approved or investigational agent.&#xD;
&#xD;
         11. Ability to swallow an oral solid-dosage form of medication.&#xD;
&#xD;
         12. A negative serum pregnancy test within 7 days prior to the first dose of study&#xD;
             medication in women of childbearing potential (that is, all women except for those who&#xD;
             are post menopause for &gt; 1 year or who have a history of hysterectomy or surgical&#xD;
             sterilization).&#xD;
&#xD;
         13. Agreement to use a highly effective form of contraception (ie, one that has a failure&#xD;
             rate of &lt; 1%) throughout the treatment phase of the study in women of childbearing&#xD;
             potential (that is, all women excluding those who are post menopause for &gt; 1 year or&#xD;
             who have a history of hysterectomy or surgical sterilization) and sexually active men&#xD;
&#xD;
         14. Written informed consent and authorization to use and disclose health information.&#xD;
&#xD;
         15. Ability to comprehend and to comply with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of brain metastasis or leptomeningeal disease.&#xD;
&#xD;
          2. Primary ocular or mucosal melanoma.&#xD;
&#xD;
          3. Second cancer (except for adequately treated basal cell or squamous cell skin cancer,&#xD;
             in situ cervical cancer, or other cancer for which the subject has been disease-free&#xD;
             for 5 or more years)&#xD;
&#xD;
          4. Human immunodeficiency virus infection based on history of positive serology.&#xD;
&#xD;
          5. Significant medical disease other than cancer, including but not limited to&#xD;
             uncontrolled diabetes mellitus, active angina or heart failure, uncontrolled&#xD;
             hypertension, or an active psychiatric condition that would prevent consistent and&#xD;
             compliant participation in the study&#xD;
&#xD;
          6. Organ allograft.&#xD;
&#xD;
          7. Presence of neuropathy &gt; Grade 1.&#xD;
&#xD;
          8. Prior treatment with a taxane or other tubulin-targeted agent (eg, indibulin) other&#xD;
             than a vinca alkaloid.&#xD;
&#xD;
          9. Need for other anticancer treatment (such as chemotherapy, radiation therapy, or&#xD;
             biologic therapy with an approved or investigational agent) while receiving protocol&#xD;
             therapy.&#xD;
&#xD;
         10. Need to continue any regularly-taken medication that is a potent inhibitor or inducer&#xD;
             of the CYP3A pathway or P-glycoprotein activity.&#xD;
&#xD;
         11. Less than 2 weeks since use of a medication or ingestion of an agent that is a potent&#xD;
             inhibitor or inducer of the CYP3A pathway or P-glycoprotein.&#xD;
&#xD;
         12. Pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agop Y. Bedikian, MD, BS</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>February 5, 2010</study_first_submitted>
  <study_first_submitted_qc>February 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2010</study_first_posted>
  <results_first_submitted>October 26, 2015</results_first_submitted>
  <results_first_submitted_qc>July 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2018</results_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tesetaxel</keyword>
  <keyword>Second-line therapy</keyword>
  <keyword>Metastatic melanoma</keyword>
  <keyword>Normal serum LDH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: August 9, 2010 to July 12, 2012. All recruitment done at the University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>No participants were enrolled in Stage 2 of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>40 mg Tesetaxel, Cohort A</title>
          <description>Therapy initiated at a flat dose of 40 mg for subjects in Cohort A. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.</description>
        </group>
        <group group_id="P2">
          <title>50 mg Tesetaxel, Cohort B</title>
          <description>Therapy initiated at a flat dose of 50 mg for subjects in Cohort B. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>40 mg Tesetaxel, Cohort A</title>
          <description>Therapy initiated at a flat dose of 40 mg for subjects in Cohort A. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.</description>
        </group>
        <group group_id="B2">
          <title>50 mg Tesetaxel, Cohort B</title>
          <description>Therapy initiated at a flat dose of 50 mg for subjects in Cohort B. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="48" upper_limit="88"/>
                    <measurement group_id="B2" value="64" lower_limit="53" upper_limit="87"/>
                    <measurement group_id="B3" value="68" lower_limit="48" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (ie, the Percentage of Subjects With a Confirmed Complete or Partial Response)</title>
        <description>Determination of response performed according to the revised Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 using computed tomography (CT). Complete response: Disappearance of all target lesions; if pathologic lymph node, reduction in shortest axis to &lt; 10 mm; Partial response: ≥ 30% decrease in sum of diameters of target lesions relative to baseline sum diameters; Stable disease: Neither a sufficient reduction to qualify as partial response nor a sufficient increase to qualify as progression; Progressive disease ≥ 20% increase in sum diameters relative to smallest sum diameters recorded (including baseline sum diameters) in conjunction with increase of least 5 mm in that smallest sum diameters, or appearance of one or more new lesions.</description>
        <time_frame>Day 84</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40 mg Tesetaxel, Cohort A</title>
            <description>Therapy initiated at a flat dose of 40 mg for subjects in Cohort A. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Tesetaxel, Cohort B</title>
            <description>Therapy initiated at a flat dose of 50 mg for subjects in Cohort B. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (ie, the Percentage of Subjects With a Confirmed Complete or Partial Response)</title>
          <description>Determination of response performed according to the revised Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 using computed tomography (CT). Complete response: Disappearance of all target lesions; if pathologic lymph node, reduction in shortest axis to &lt; 10 mm; Partial response: ≥ 30% decrease in sum of diameters of target lesions relative to baseline sum diameters; Stable disease: Neither a sufficient reduction to qualify as partial response nor a sufficient increase to qualify as progression; Progressive disease ≥ 20% increase in sum diameters relative to smallest sum diameters recorded (including baseline sum diameters) in conjunction with increase of least 5 mm in that smallest sum diameters, or appearance of one or more new lesions.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Response</title>
        <description>Determination of response performed according to the revised Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 using computed tomography (CT). Complete response: Disappearance of all target lesions; if pathologic lymph node, reduction in shortest axis to &lt; 10 mm; Partial response: ≥ 30% decrease in sum of diameters of target lesions relative to baseline sum diameters; Stable disease: Neither a sufficient reduction to qualify as partial response nor a sufficient increase to qualify as progression; Progressive disease ≥ 20% increase in sum diameters relative to smallest sum diameters recorded (including baseline sum diameters) in conjunction with increase of least 5 mm in that smallest sum diameters, or appearance of one or more new lesions.</description>
        <time_frame>Day 84</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40 mg Tesetaxel, Cohort A</title>
            <description>Therapy initiated at a flat dose of 40 mg for subjects in Cohort A. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Tesetaxel, Cohort B</title>
            <description>Therapy initiated at a flat dose of 50 mg for subjects in Cohort B. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response</title>
          <description>Determination of response performed according to the revised Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 using computed tomography (CT). Complete response: Disappearance of all target lesions; if pathologic lymph node, reduction in shortest axis to &lt; 10 mm; Partial response: ≥ 30% decrease in sum of diameters of target lesions relative to baseline sum diameters; Stable disease: Neither a sufficient reduction to qualify as partial response nor a sufficient increase to qualify as progression; Progressive disease ≥ 20% increase in sum diameters relative to smallest sum diameters recorded (including baseline sum diameters) in conjunction with increase of least 5 mm in that smallest sum diameters, or appearance of one or more new lesions.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Initiation of therapy through end of treatment (through 30 days after the last dose of study medication), up to 7 cycles of 21 day therapy.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>40 Tesetaxel, Cohort A</title>
          <description>Therapy initiated at a flat dose of 40 mg for subjects in Cohort A. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.</description>
        </group>
        <group group_id="E2">
          <title>50 mg Tesetaxel, Cohort B</title>
          <description>Therapy initiated at a flat dose of 50 mg for subjects in Cohort B. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>taste alteration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>headaches</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>peripheral neuropathies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Agop Y. Bedikian, MD/Professor</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

